Clinical trials: Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This single arm, post-authorisation study is designed to evaluate the long-term safety of pirfenidone in participants with IPF. The enrolment of participants will be completed within approximately 24 months.
- Trial name
- NCT02699879
- Testing
- Pirfenidone
- Where
- 106 sites in Austria, Denmark and 8 more
- Volunteers
- 1,009 people
- Sponsor
- Hoffmann-La Roche
Cystic Fibrosis
Trikafta in Cystic Fibrosis Patients
This clinical study will enroll 42 participants without the F508del mutation, carrying partial function or N1303K mutations not approved for Trikafta, and who are not expected to be approved for CFTR modulator treatment in the…
- Trial name
- NCT03506061
- Testing
- Trikafta
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Emory University
Bronchial Asthma, Pulmonary Cystic Fibrosis
Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.
Exhaled breath condensate (EBC) represents a rich source for countless biomarkers that can provide valuable information about respiratory as well as systemic diseases.
- Trial name
- NCT04157361
- Testing
- Collection of breath condensate
- Where
- Czechia
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- The Institute of Molecular and Translational Medicine, Czech Republic
Cancer Risk, Cancer Predisposition Syndrome
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member…
- Conditions
- Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors
- Trial name
- NCT05463796
- Testing
- Samples
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Cystic Fibrosis
CFfone: A Cell Phone Support Program for Adolescents With Cystic Fibrosis
Adolescents with cystic fibrosis are particularly vulnerable to poor adherence, which negatively impacts their health status, quality of life and long term survival.
- Trial name
- NCT01183286
- Testing
- CFFONE, CF website
- Volunteers
- 146 people
- Sponsor
- Dawkins Productions, Inc.
Healthy, Cystic Fibrosis (CF)
MRI for Non-Invasive Imaging in Neonates and Children
The purpose of this study is to develop rapid MRI techniques for imaging the lung with hyperpolarized helium-3 gas as an inhaled contrast agent.
- Conditions
- Healthy, Cystic Fibrosis (CF), Asthma, Bronchopulmonary Dysplasia (BPD)
- Trial name
- NCT02163681
- Testing
- Hyperpolarized Helium-3 MRI of the chest
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Cystic Fibrosis
Miglustat in Cystic Fibrosis
Single Center, Double-Blind, Randomized, Placebo-Controlled, Two-Period/Two-Treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the…
- Trial name
- NCT00742092
- Testing
- miglustat
- Where
- Belgium
- Volunteers
- 11 people
- Sponsor
- Actelion
Cystic Fibrosis (CF)
Sweat Testing in Infants: Comparing Sweat Collection on Upper Vs Lower Limbs
The goal of this study is to compare the rate of Quantity Not Sufficient (QNS) during sweat collection in infants under 6 months of age, using the Macroduct Advanced device for sweat testing.
- Trial name
- NCT06902363
- Testing
- Macroduct Advanced
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Cystic Fibrosis (CF)
Population Pharmacokinetics of Elexacaftor-tezacaftor-ivacaftor in a Paediatric Population
Cystic fibrosis is a rare, progressive genetic disease caused by a mutation in the CFTR (cystic fibrosis transmembrane conductance regulator) gene. Respiratory and nutritional effects are crucial to patients' prognosis.
- Trial name
- IMPROVED (NCT07303621)
- Testing
- There is no intervention as this is a prospective pharmacokinetics study.
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Hospices Civils de Lyon
Cystic Fibrosis
Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation
The purpose of this study is to provide information regarding the long-term safety and pharmacodynamics of ivacaftor treatment in the pediatric population younger than 6 years of age with Cystic Fibrosis (CF) who have a CFTR…
- Trial name
- NCT01946412
- Testing
- Ivacaftor
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 33 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
Part 1 is a study to demonstrate that Creon (pancrelipase) delayed release (DR) capsules manufactured with a modernized process (MP) is non-inferior to currently marketed pancrelipase DR capsules in participants with exocrine…
- Trial name
- NCT03924947
- Testing
- Pancrelipase
- Where
- 13 sites in United States
- Volunteers
- 36 people
- Sponsor
- AbbVie
Inflammatory Changes in Epithelial Lining Fluid Sampled Non-invasively by Nasal Lavage in CF Patients With G551D Receiving Kalydeco
Effects of Kalydeco on Upper Airway and Paranasal Sinus Inflammation Measured by Nasal Lavage and on Symptoms
The aim of the proposed trial in assessment of effects of Kalydeco™ treatment on sinonasal involvement in CF patients with at least one mutation of G551D receiving a new therapy with the CFTR potentiator.
- Trial name
- KPNSI (NCT02311140)
- Testing
- nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University of Jena
Cystic Fibrosis, Asthma
Segmentation of Structural Abnormalities in Chronic Lung Diseases
Lung structural abnormalities are complex, time-consuming, and may lack reproducibility to evaluate visually on CT scans. The study's aim is to perform automated recognition of structural abnormalities in CT scans of patients…
- Conditions
- Cystic Fibrosis, Asthma, COPD, Interstitial Lung Disease
- Trial name
- NOVAA (NCT04760548)
- Testing
- Observational study
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Hôpital Haut Lévêque
Cystic Fibrosis
A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes
The study evaluates the long-term safety and efficacy of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) triple combination (TC) in participants with CF who are 6 years of age and older with F/MF genotypes.
- Trial name
- NCT04545515
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 34 sites in Australia, Canada and 8 more
- Volunteers
- 120 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Idiopathic Pulmonary Fibrosis, Gastroesophageal Reflux
Treatment of IPF With Laparoscopic Anti-Reflux Surgery
This study will test the hypothesis that treatment with laparoscopic anti-reflux surgery in subjects with idiopathic pulmonary fibrosis (IPF) and abnormal gastroesophageal reflux (GER) will slow the decline of forced vital…
- Trial name
- WRAP-IPF (NCT01982968)
- Testing
- Surgery
- Where
- 5 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of California, San Francisco
Cystic Fibrosis
Glycemic Monitoring in Cystic Fibrosis
Current guidelines on the diagnoses and management of cystic fibrosis (CF) related diabetes recommend treatment for diabetes based on diagnostic criteria derived from adults with type 2 diabetes.
- Trial name
- GEM (NCT02211235)
- Where
- United States
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Cystic Fibrosis
Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation
This is a Phase 3, multicenter, open-label and roll-over study in participants who are 12 to <24 months of age at initiation of Lumacaftor/Ivacaftor (LUM/IVA) treatment.
- Trial name
- NCT04235140
- Testing
- LUM/IVA
- Where
- 23 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cystic Fibrosis
International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa
The purpose of this study was to evaluate the safety and efficacy of a 28-day course of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF1 (NCT00112359)
- Testing
- AZLI 75 mg three times a day (TID)
- Where
- 53 sites in United States, Australia and 2 more
- Volunteers
- 166 people
- Sponsor
- Gilead Sciences
Cystic Fibrosis
Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis
Investigation of the influence of giving DHA-rich supplement versus placebo on DHA-status and health evolution of patients with cystic fibrosis
- Trial name
- NCT00221546
- Testing
- Giving DHA-rich supplement
- Where
- Belgium
- Volunteers
- 17 people
- Sponsor
- University Hospital, Ghent
Cystic Fibrosis (CF)
MAGNIFY - Pulmonary Magnetic Resonance Imaging for Cystic Fibrosis
This research study is looking at new ways of measuring the function of the lungs in patients with cystic fibrosis. This study is using the most advanced methods for measuring lung function including 2 tests called hyperpolarised…
- Trial name
- MAGNIFY (NCT07192679)
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust